Roles of clinical application of lenvatinib and its resistance mechanism in advanced hepatocellular carcinoma (Review).

IF 3.6 3区医学 Q2 ONCOLOGY

American journal of cancer research Pub Date : 2024-09-15 eCollection Date: 2024-01-01 DOI:10.62347/UJVP4361

Ganghui Ye, Meng Ye, Xiaofeng Jin

{"title":"Roles of clinical application of lenvatinib and its resistance mechanism in advanced hepatocellular carcinoma (Review).","authors":"Ganghui Ye, Meng Ye, Xiaofeng Jin","doi":"10.62347/UJVP4361","DOIUrl":null,"url":null,"abstract":"<p><p>Lenvatinib (LEN) is a multi-target TKI, which plays a pivotal role in the treatment of advanced hepatocellular carcinoma (HCC). The inevitable occurrence of drug resistance still prevents curative potential and is deleterious for the prognosis, and a growing body of studies is accumulating, which have devoted themselves to unveiling its underlying resistance mechanism and made some progress. The dysregulation of crucial signaling pathways, non-coding RNA and RNA modifications were proven to be associated with LEN resistance. A range of drugs were found to influence LEN therapeutic efficacy. In addition, the superiority of LEN combination therapy has been shown to potentially overcome the limitations of LEN monotherapy in a series of research, and a range of promising indicators for predicting treatment response and prognosis have been discovered in recent years. In this review, we summarize the latest developments in LEN resistance, the efficacy and safety of LEN combination therapy as well as associated indicators, which may provide new insight into its resistance as well as ideas in the treatment of advanced HCC.</p>","PeriodicalId":7437,"journal":{"name":"American journal of cancer research","volume":"14 9","pages":"4113-4171"},"PeriodicalIF":3.6000,"publicationDate":"2024-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11477829/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American journal of cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.62347/UJVP4361","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Lenvatinib (LEN) is a multi-target TKI, which plays a pivotal role in the treatment of advanced hepatocellular carcinoma (HCC). The inevitable occurrence of drug resistance still prevents curative potential and is deleterious for the prognosis, and a growing body of studies is accumulating, which have devoted themselves to unveiling its underlying resistance mechanism and made some progress. The dysregulation of crucial signaling pathways, non-coding RNA and RNA modifications were proven to be associated with LEN resistance. A range of drugs were found to influence LEN therapeutic efficacy. In addition, the superiority of LEN combination therapy has been shown to potentially overcome the limitations of LEN monotherapy in a series of research, and a range of promising indicators for predicting treatment response and prognosis have been discovered in recent years. In this review, we summarize the latest developments in LEN resistance, the efficacy and safety of LEN combination therapy as well as associated indicators, which may provide new insight into its resistance as well as ideas in the treatment of advanced HCC.

查看原文本刊更多论文

来伐替尼在晚期肝细胞癌中的临床应用及其耐药机制（综述）。

伦伐替尼（LEN）是一种多靶点TKI，在晚期肝细胞癌（HCC）的治疗中发挥着举足轻重的作用。不可避免的耐药性仍然阻碍着治疗的潜力，并对预后产生不利影响，越来越多的研究致力于揭示其潜在的耐药机制，并取得了一些进展。关键信号通路、非编码 RNA 和 RNA 修饰的失调被证实与 LEN 耐药有关。研究还发现一系列药物会影响 LEN 的疗效。此外，一系列研究表明，LEN 联合疗法的优越性有可能克服 LEN 单药疗法的局限性，近年来还发现了一系列预测治疗反应和预后的指标。在这篇综述中，我们总结了LEN耐药性、LEN联合疗法的疗效和安全性以及相关指标的最新进展，这或许能为了解其耐药性提供新的视角，并为晚期HCC的治疗提供思路。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

American journal of cancer research ONCOLOGY-

自引率

3.80%

发文量

263

期刊介绍： The American Journal of Cancer Research (AJCR) (ISSN 2156-6976), is an independent open access, online only journal to facilitate rapid dissemination of novel discoveries in basic science and treatment of cancer. It was founded by a group of scientists for cancer research and clinical academic oncologists from around the world, who are devoted to the promotion and advancement of our understanding of the cancer and its treatment. The scope of AJCR is intended to encompass that of multi-disciplinary researchers from any scientific discipline where the primary focus of the research is to increase and integrate knowledge about etiology and molecular mechanisms of carcinogenesis with the ultimate aim of advancing the cure and prevention of this increasingly devastating disease. To achieve these aims AJCR will publish review articles, original articles and new techniques in cancer research and therapy. It will also publish hypothesis, case reports and letter to the editor. Unlike most other open access online journals, AJCR will keep most of the traditional features of paper print that we are all familiar with, such as continuous volume, issue numbers, as well as continuous page numbers to retain our comfortable familiarity towards an academic journal.